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Introduction. Models are mathematical representations of real systems. To predict the 
behaviour of the real system with as small deviation as possible, model structure selection 
and model parameters estimation should be performed in a systematic procedure referred to 
as model identification. This task can be quite challenging for heterogeneous biological 
systems such as wastewater, which are usually described with rather complex mathematical 
formulations in order to properly represent the interactions between multiple types of 
microorganisms. A typical drawback of such models is over-parametrization, causing non-
identifiability of model parameters. This issue can cause more problems when 
measurements are scarce and data quality is poor. Parameter identifiability issues can be 
tackled with effective experimental design combined with multi-faceted parameter estimation 
protocols, such as sensitivity analysis, parameter correlation, or iterative procedures (Brun et 
al., 2002; Mannina et al., 2011; Sin et al., 2005). However, these procedures are not reported 
for all biological processes and systems. For instance, despite increasing popularity of 
micropollutants fate models (e.g., Plósz et al., 2012; Polesel et al., 2016) in wastewater, the 
challenges related to model identification are less understood and addressed. The main 
objective of this study includes the development of a model-based identification method for 
multi-branched chemical transformation pathways combined with reaction kinetics models. 
The outcome can serve as a complementary tool for chemical pathway identification, which 
are commonly characterized by analytical chemistry methods. Heroin and codeine together 
with 4 other human metabolites in wastewater were considered as case study.  
 
Methods. Transformation of heroin (HER) drug biomarkers and its human metabolites, 6-
monoacetylmorphine (6-MAM), morphine (MOR), and morphine-3-β-D-glucuronide (MORG), 
(COE) and its human metabolite norcodeine (NCOE) in untreated wastewater under 
anaerobic conditions were used as case study. Specific details regarding the experimental 
assessment and process model development are presented by Ramin et al (2016). The 
model includes kinetic parameters, namely abiotic transformation rates, kabio (d
-1), and 
biotransformation rate constants, kbio (L g TSS d
-1), for each selected drug biomarker. 
Through model calibration against batch experimental, these parameters were estimated 
using the Bayesian optimization algorithm DREAM(ZS) (Laloy and Vrugt, 2012) following three 
different methods. Method 1 is the proposed method of choice, whilst the two other methods 
are commonly encountered in literature: 
 Method 1: parameter estimation is performed by considering parameter ranges and 
associated probability distributions obtained at any given transformation pathway 
level as priors for parameter estimation at any subsequent transformation levels. 
 Method 2: parameters are estimated in a concerted way and by omitting a priori 
information regarding the range and the parameter probability distribution – also 
referred to as the “lumped” estimation method.  
 Method 3: Parameters are estimated using a step-wise approach (as in Method 1) by 
employing fixed parameter values via parameter estimation at downstream levels 




Model accuracy predictions derived using the three different calibration methods were 
assessed using statistical tests. Values obtained for the Root Mean Squared Error (RMSE) 
and the Mean Absolute Error (MAE) were related to model prediction accuracy, i.e. the lower 
the RMSE and MAE, the more accurate the model prediction. Additionally, the average 
relative Interval Length to Coverage of measurements by prediction bands (ILTC) was used 
for model prediction unertainty. A lower ILTC provides an indication of lower prediction 
uncertainty together with higher coverage of measured values by the uncertainty band. 
 
Results.  An overview of identification methodology (Method 1) is presented in Fig. 1a. The 
method involves three stages: (I) estimation of parameters at defined levels; (II) evaluation of 
model structure (i.e., kinetic and/or pathway) at each level; and (III) propagation of parameter 
uncertainty to the subsequent levels. The estimation methodology consists of n levels, 
defined according to assumed abiotic (A) and biotic (B) reaction pathways. The chemical 
pathway is represented by m chemicals (from X1 to Xm) transformed via abiotic (e.g., 
hydrolysis) and microbially-mediated reactions. In the case of systematic error in the model 
prediction, the structure of the kinetic model (e.g., second-order or first-order kinetics) and 
the chemical transformation pathway (e.g., new transformation products) are re-evaluated 
(Fig. 1b). This iterative approach ensures that uncertainty of parameters would only 
propagate if the model structure is adequately describing the system. Following our previous 
study (Ramin et al., 2016) it is assumed that the structure of the model is sufficiently precise.  
As to the transformation pathway of HER and its metabolites, the histograms from Method 1 
and Method 3 (Fig. 2, red bars and solid black lines) show that for most parameters the 
posterior distributions are skewed (e.g., significant positive skewness for MOR (B1)). This is 
not the case for most of the parameter subsets obtained using Method 2, showing 
comparably higher values and predominantly wider uniform distribution. Following parameter 
estimation, the impact of parameter uncertainty on model outputs (drug concentrations) was 
assessed through uncertainty analysis using Monte Carlo simulations (Fig. 3). These results 
suggest that Method 2 can lead to estimates with higher uncertainties for both abiotic and 
biotic model parameters. The prediction accuracy obtained using Method 1 and Method 3 
(Table 1) showed comparable performance in the biotic model, except for MOR and 6-MAM, 
for which Method 1 resulted in higher accuracy, and for MORG, where Method 3 showed a 
better performance. Based on the collinearity threshold for identifiability (0.7;Sin et al., 2009) 
), all estimated parameters from all methods were identifiable except the parameters related 
to the chemicals with two transformation branches in Method 3 (i.e., HER and MORG 
transformation pathways, Fig. 4).  
Overall, these results indicate that Method 1, compared to the other two methods, can 
improve the identifiability of model parameters whilst maintaining a good prediction 
performance.   
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Figure 1. Overview of the proposed identification method, i.e., model calibaration (a) and model structure analysis 
(b), referred to as Method 1 in this study, to estimate transformation rate constants in metabolic pathway models 
for both abiotic and biotic processes. The method includes n calibration levels for m number of metabolites (e.g., 
X1 to Xm). 
 
 
Figure 2. The identified transformation pathway of heroin (HER) and codeine (COE) drug biomarkers, including 
abiotic and biotic processes. Posterior distribution of estimated parameters (histograms) for the proposed 
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Figure 3. Measured and simulated biomarker concentration data with uncertainty bands obtained using Method 
1-3. Markers are measured data and lines are simulation results. The shaded area reflects 95% credibility interval 
of model prediction (red area and full line: Method 1; gray area and dashed line: Method 2; blue area and dotted 
line: Method 3). 
 
Table 1. Assessment of simulation accuracy of models calibrated using Methods 1-3. Abbreviations: RMSE, root 
mean squared error; MAE, mean absolute error; ILTC, interval length to coverage. For better comparison among 





Figure 4. Linear correlation coefficients for model parameters following parameter estimation in calibration 
Method 1-3. Correlation threshold for identifiability defined at 0.7 according to Sin et al. (2009). Positive and 
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RMSE 0.62 3.91 0.62    0.31 4.60 0.25 0.28 1.74 0.29 0.58 4.93 0.49 0.29 2.58 0.46 
MAE 0.42 2.98 0.42  na.  0.24 3.44 0.18 0.23 1.14 0.25 0.40 3.74 0.35 0.26 1.74 0.36 











RMSE 0.25 1.25 0.25 1.58 5.72 1.54 0.29 2.25 0.27 0.19 0.40 0.18 0.23 3.89 0.23 0.57 4.52 1.41 
MAE 0.14 0.78 0.13 1.05 3.74 0.93 0.23 1.34 0.20 0.12 0.24 0.12 0.17 3.02 0.19 0.43 3.38 0.87 
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